论文部分内容阅读
目的 探讨原发性肝癌术后抗复发对策，及以再切除为主的综合治疗措施的远期疗效。方法 对我院自１９６０ 年１ 月至１９９６ 年５ 月间１６２ 例原发性肝癌术后复发行再切除者的临床特点、手术方法和预后进行回顾性分析。结果 全组１、３、５、１０ 年总生存率分别为９６．８％ 、６６．７ ％ 、４３ ．６％ 和２１．８％ 。中位生存期３ 年９ 个月，平均生存期４ 年５ 个月；其中肝内复发组１２６ 例术后１、３、５、１０ 年生存率分别为９９．２％ 、７１．３％ 、４６．６％和１９．１％ ，二次肝切除术后１、３、５ 年生存率分别为８３．５ ％ 、３８．２％ 和１９ ．６ ％ ，三次肝切除术后１ 、３、５ 年生存率分别为９４．７％ 、４４ ．９ ％ 和２５．０％ ；肝外转移组３０ 例首次肝切除术后１、３、５ 年生存率分别为８９ ．７％ 、６１．０ ％ 和３２．６％ ，二次肝外转移灶切除术后１、３、５ 年生存率分别为７５ ．４％ 、２９．０ ％ 和１５．６％ ；兼行肝内复发癌和肝外转移灶切除组共６ 例，现存活３ 例，手术至今分别为１ 年１０ 个月，３ 年９ 个月和９ 年９ 个月。另３ 例相继于术后３年１１ 个月、５ 年８ 个月和６ 年１１ 个月死亡。结论 复发的原因与门静脉癌栓及肿瘤多中?
Objective To investigate the anti-recurrence strategies for primary liver cancer after operation and the long-term efficacy of comprehensive treatment measures based on re-excision. Methods The clinical features, surgical methods and prognosis of 162 patients undergoing recurrent resection of primary liver cancer from January 1960 to May 1996 were retrospectively analyzed. Results The overall 1-, 3-, 5-, and 10-year overall survival rates were 96.8%, 66.7 %, and 43. 6% and 21.8%. The median survival period was 3 years and 9 months, and the average survival time was 4 years and 5 months. Among them, 126 patients in the intrahepatic recurrence group had a postoperative survival rate of 99.2% and 71.3% at 1, 3, 5 and 10 years, respectively. At 46.6% and 19.1%, the 1-, 3-, and 5-year survival rates after secondary hepatectomy were 83.5%, 38.2%, and 19, respectively. At 6 %, the 1-, 3-, and 5-year survival rates after three hepatectomy were 94.7% and 44 respectively. Ninety percent and 25.0% of the patients who received extrahepatic metastasis had a 1-, 3-, and 5-year survival rate of 30 after the first liver resection. 7%, 61.0%, and 32.6%. The survival rate after resection of secondary extrahepatic metastases was 1, 3, and 5 years, respectively. 4%, 29.0%, and 15.6%; Intrahepatic recurrent cancer and extrahepatic metastases resection group consisted of 6 cases, and 3 cases survived. The operation so far has been 1 year 10 months, 3 years 9 months and 9 years and 9 months. The other 3 patients died 3 years 11 months, 5 years 8 months and 6 years 11 months after surgery. Conclusion The reasons for recurrence and portal vein tumor emboli and tumors are many?